The state of Florida currently has 203 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: AdventHealth Medical Group, Altamonte Springs, Florida +40 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT06388122
Recruiting
The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer
Register for Updates
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT05856773
Recruiting
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/14/2025
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida +1 locations
Conditions: Breast Cancer
Register for Updates
Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193
Recruiting
This is a first-in-human, open-label, multicenter phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Broward Health Medical Center, Fort Lauderdale, Florida +3 locations
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
NCT06728579
Recruiting
The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of joint pain is called AI-associated arthralgia, or AIA, and it is common in people taking AIs. AIA and its associated symptoms can make some people decide to stop taking their medication. The study will look at the effects of two different types of group therap... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Florida State University, Tallahassee, Florida
Conditions: Breast Cancer Survivor
Register for Updates
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
Recruiting
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
Recruiting
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a type of antibody-drug conjugate) * Trastuzumab (Herceptin) (a type of monoclonal antibody) * Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) * Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Miami Cancer Institute at Baptist Health, Miami, Florida
Conditions: Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
Register for Updates
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT06691035
Recruiting
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT06327490
Recruiting
Breast cancer is estimated to affect approximately 300,000 women in the US in 2023. Studies demonstrate that 1 in 5 will develop breast cancer related lymphedema secondary to the treatments that they receive. BCRL at this time has no cure, however early detection can prevent the progression to late stage BCRL. At this time a technique of arm massage, manual lymphatic drainage (MLD), is used for treatment. This study investigates a new method of MLD, which is guided by the individual patients' ly... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT06409390
Recruiting
The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Metastatic Breast Cancer
Register for Updates
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: John Fitzgerald Kennedy Medical Center, Atlantis, Florida +13 locations
Conditions: Breast Cancer, Cognitive Impairments
Register for Updates